Pulmonx Corp(LUNG)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Pulmonx Corp (LUNG) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LUNG at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,725 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.7) and balance sheet strength (5.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Pulmonx Corp reports quarterly revenue of $22.8M, net income of $-10.1M, free cash flow of $-5.2M. Top institutional holders of LUNG by reported 13-F value include PRIMECAP MANAGEMENT, MORGAN STANLEY, Soleus Capital Management, L.P., based on the most recent SEC filings. LUNG trades on the Nasdaq exchange and files with the SEC under CIK 1127537. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUNG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pulmonx Corp directly from SEC EDGAR.